Introduction {#tca12790-sec-0005}
============

Although the repeated pulmonary resections of local regional recurrent or second primary lung cancers have long been performed in clinical practice, little is known about their oncological effectiveness and surgical safety. With the development of modern medical imaging, minimally invasive surgery, molecular pathology, and systematic treatment for lung cancer, multiple pulmonary resections (MPRs) are frequently performed in modern clinical practice. MPRs are suitable for a wide range of applications, including the following: (i) the curative management of multiple primary lung cancer (synchronous and metachronous), in conjunction with the widespread utilization of lung cancer screening and intense follow‐up after prior surgery; (ii) a local consolidation treatment modality in the era of oligometastasis and oligorecurrence; (iii) the removal of residual disease after systematic treatment, such as chemotherapy, targeted therapy, or immunotherapy; and (iv) the robust tissue retrieval approach for precise staging and molecular analysis, compared with fine needle aspiration. In this study, we reviewed more than 1800 primary lung cancer cases from our prospective lung cancer database and determined the oncological efficacy and surgical safety of MPR for local regional recurrent or second primary lung cancers.

Methods and patients {#tca12790-sec-0006}
====================

The data of all primary lung cancer patients included in our prospective database between January 2000 and July 2015 were consecutively reviewed to identify MPR cases. The inclusion criteria were as follows: (i) patients who underwent either synchronous or metachronous MPR, and (ii) patients who had at least one tumor that was pathologically confirmed as primary lung cancer. Any patients who underwent bilobectomy via a single procedure because of the involvement of two neighboring lobes were excluded.

A propensity score‐matched group of patients who underwent solitary major pulmonary resection (case--control ratio 1:5) was used as the control group for comparison with the synchronous MPR group in terms of survival. All patients with local regional recurrent or second primary lung cancer after the prior operation treated with a non‐surgical approach were used as the control group for comparisons with the metachronous MPR group in terms of survival. The control group for surgical safety consisted of solitary major pulmonary resection patients.

Diagnosis, staging, and follow‐up protocols {#tca12790-sec-0007}
-------------------------------------------

Our diagnostic, staging, and follow‐up protocols for patients with lung cancer at Peking University Cancer Hospital include contrast‐enhanced chest computed tomography (CT) including bilateral adrenals with or without CT‐guided transthoracic biopsy, bilateral supraclavicular and upper abdominal ultrasonography, cranial magnetic resonance imaging, whole‐body bone scintigraphy or positron emission tomography‐CT, and flexible bronchoscopy with or without transbronchial biopsy. Other appropriate studies were performed to exclude extrapulmonary primary cancer that might affect the diagnoses and treatment options.

When resection was contemplated, a full biochemical analysis, an electrocardiogram, and pulmonary function tests were obtained. In addition, all patients evaluated for the repeated surgery had a second quantitative pulmonary function test to estimate the postoperative maximum forced expiratory volume in 1 second and the percentage of forced vital capacity. All lesions were clinically and pathologically staged according to the eighth edition of the International Staging System of Lung Cancer as proposed by the American Joint Committee on Cancer.[1](#tca12790-bib-0001){ref-type="ref"}

All patients who underwent resection for lung cancer at our institution were followed‐up at the outpatient clinic quarterly for the first two years, semiannually for the following two years, and annually thereafter for life. Patient history and a physical examination along with a chest CT scan and bilateral supraclavicular and upper abdominal ultrasonography were obtained at each clinic visit. Moreover, whole‐body bone scintigraphy or positron emission tomography‐CT scan and cranial magnetic resonance imaging were obtained every six months.

Study endpoints {#tca12790-sec-0008}
---------------

The oncological efficacy endpoints were as follows: (i) overall survival (OS) was calculated from the date of the first operation to the date of last follow‐up or death; (ii) disease‐free survival (DFS) of synchronous MPR was calculated from the date of the first operation to the date of the last follow‐up, disease relapse, or death; and (iii) progression‐free survival (PFS) of metachronous MPR was calculated from the date of local regional disease relapse/second primary lung cancer to the date of last follow‐up, disease relapse, or death. The objective Response Evaluation Criteria in Solid Tumors version 1.1 was used to categorize response.[2](#tca12790-bib-0002){ref-type="ref"} The final follow‐up was conducted in September 2017.

The surgical safety endpoints were as follows: (i) postoperative mortality, including death from any cause, occurring within 30 days of surgery or beyond 30 days during the same hospitalization; and (ii) the definitions of postoperative complications were in accordance with those of the Society of Thoracic Surgeons General Thoracic Surgery Database,[3](#tca12790-bib-0003){ref-type="ref"} while the severity of postoperative complications was evaluated by the Clavien‐Dindo classification.[4](#tca12790-bib-0004){ref-type="ref"}

Statistical analysis {#tca12790-sec-0009}
--------------------

The survival probability was calculated by the Kaplan--Meier actuarial method, with the date of procedure as the starting point, and including death from any causes. The log rank test was used to compare survival rates between groups. A *P* value of 0.050 was considered statistically significant. Propensity score matching was used to reduce bias in the comparison of MPR to a non‐randomized control group. SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) was used to perform statistical analysis. An SAS Macro, OneToManyMTCH, was applied to complete the 1:5 case--control propensity score matching. The graphs were prepared using GraphPad Prism version 6.01 (GraphPad Software Inc., La Jolla, CA, USA).

Results {#tca12790-sec-0010}
=======

Sixty‐seven MPR cases (42 men and 25 women) were identified among the 1887 primary lung cancer patients in our prospective database between January 2000 and July 2015. The median age at initial diagnosis was 62 years (range: 35--77). Twenty‐one patients (31%) had a history of smoking at the time of the first primary lung cancer diagnosis. Fifty patients (75%) underwent synchronous MPR and 17 (25%) underwent metachronous MPR. The median interval for metachronous MPR was 41 months (range: 16--90). Lesions were located in the unilateral lungs in 38 (57%) patients; 33 of these patients underwent synchronous MPR and 5 underwent metachronous MPR. Lesions were located in the bilateral lungs in 29 (43%) patients; 17 patients underwent synchronous MPR and 12 underwent metachronous MPR. Twenty‐nine (45%) patients had tumors exceeding 40 mm. There were 48 patients (72%) with stage I lung cancer, 4 (6%) with stage II, 3 (4%) with stage III, 8 (13%) with stage IV, and 4 patients with unspecified staging as prior procedures were performed at other hospitals. Among the 50 synchronous MPR patients, there were 40 patients at stage N0, 2 at stage N1, and 8 patients at stage N2. Among the 17 metachronous MPR patients, there were 14 patients at stage N0, 1 at stage N1, and 2 patients at stage N2 at the first resection and 17 patients at stage N0 at the second resection. Ten (15%) patients received neoadjuvant therapy and 24 (36%) received adjuvant therapy. The median duration of follow‐up after the first operation was 53 months (range: 7--235) (Table [1](#tca12790-tbl-0001){ref-type="table"}).

###### 

Demographic and clinicopathologic characteristics of lung cancer patients with MPR (*n* = 67)

  Items                                                                             N (%)
  ------------------------------------------------------------------------------- ---------
  Age (years)                                                                     
  \< 60                                                                            19 (28)
  ≥ 60                                                                             48 (72)
  Gender                                                                          
  Male                                                                             42 (63)
  Female                                                                           25 (37)
  Smoking history                                                                 
  Yes                                                                              21 (31)
  No                                                                               46 (69)
  Temporal pattern                                                                
  Synchronous                                                                      50 (75)
  Metachronous                                                                     17 (25)
  Location distribution                                                           
  Unilateral                                                                       38 (57)
  Bilateral                                                                        29 (43)
  Radiographic pattern[†](#tca12790-note-0001){ref-type="fn"}                     
  GGO + GGO                                                                         6 (9)
  GGO + Solid nodule                                                               15 (23)
  Solid nodule + Solid nodule                                                      44 (68)
  Histological type                                                               
  ADC only                                                                         48 (72)
  ADC + non‐ADC                                                                     5 (7)
  Non‐ADC + non‐ADC                                                                14 (21)
  Sum of size (mm)                                                                
  ≤ 40                                                                             36 (55)
  \> 40                                                                            29 (45)
  Clinical TNM staging[§](#tca12790-note-0003){ref-type="fn"}                     
  IA--IB                                                                           48 (72)
  IIA--IIB                                                                          4 (6)
  IIIA                                                                              3 (4)
  IVA--IVB                                                                         8 (12)
  Unspecified                                                                       4 (6)
  Extent of resection                                                             
  Lobectomy + lobectomy                                                            13 (19)
  Lobectomy + sublobar resection                                                   46 (70)
  Sublobar resection + sublobar resection                                           4 (6)
  Bi‐lobectomy + sublobar resection                                                 1 (1)
  Lobectomy/sublobar resection + radiotherapy                                       2 (3)
  Chest wall resection + lobectomy                                                  1 (1)
  Severity of postoperative complication[¶](#tca12790-note-0004){ref-type="fn"}   
  0                                                                                 5 (8)
  I                                                                                40 (60)
  II                                                                               17 (24)
  IIIa                                                                              5 (8)
  Neoadjuvant chemotherapy                                                        
  Yes                                                                              10 (15)
  No                                                                               57 (85)
  Adjuvant chemotherapy                                                           
  Yes                                                                              24 (36)
  No                                                                               43 (64)

The radiographic patterns and

^‡^the sums of 65 cases were available.

According to the 8th Tumor Node Metastasis (TNM) staging system formulated by the Union for International Cancer Control/American Joint Committee on Cancer.

According to the Clavien‐Dindo classification. ADC, adenocarcinoma; GGO, ground glass opacity; MPR, multiple pulmonary resection.

The predominant extent of resection was lobectomy plus sublobar resection (46 patients, 70%), followed by lobectomy plus lobectomy (13 patients, 19%). Among the 50 synchronous and 17 metachronous MPR patients, 29 (58%) and 13 (76%) underwent wedge resection, respectively. Among 17 patients who underwent synchronous MPR for bilateral lungs, the following five surgical strategies were used: (i) sublobar resection followed by lobectomy (*n* = 10); (ii) lobectomy followed by lobectomy (*n* = 2); (iii) lobectomy followed by sublobar resection (*n* = 3); (iv) sublobar resection followed by sublobar resection (*n* = 1); and (v) other treatment strategies, including chest wall resection (*n* = 1) (Table [2](#tca12790-tbl-0002){ref-type="table"}).

###### 

Clinicopathologic characteristics and surgical strategies of the 17 cases with synchronous MPR in bilateral lungs

  Items No.    Lesion 1   Lesion 2   Surgical Strategy                                                  
  ----------- ---------- ---------- ------------------- -------- ---- ------- -------- ----- ----- ---- ---
  1               RL       24\*9            No            ADC     1c    LU     15\*14   No    ADC   1b   A
  2               RL       18\*13           No            ADC     2a    LU     25\*15   Yes   ADC   1c   A
  3               LU       12\*10           Yes           ADC     1b    RU     15\*13   No    ADC   1b   A
  4               LU        9\*9            Yes           ADC     1a    RU     19\*17   No    ADC   2a   A
  5               LL       15\*15           Yes           ADC     1a   RL/RM   30\*30   No    ADC   2a   A
  6               LU        5\*5            No            ADC     1a    RU     28\*20   No    ADC   2a   A
  7               RU       11\*11           Yes           ADC     1b    LL     28\*26   No    ADC   2a   A
  8               RL       21\*17           No            ADC     2a    LL     27\*23   No    ADC   2a   A
  9               LL       12\*10           No           Benign   NA    RU     35\*27   No    ADC   1c   A
  10              RU        4\*4            No           Benign   NA   LU/LL   26\*15   Yes   ADC   1b   A
  11              LL       27\*15           No            ADC     2a    RL     11\*10   No    ADC   1a   B
  12              LU       35\*30           No            SQC     2a    RU     10\*10   No    SQC   1a   B
  13              LU       54\*41           No            ADC     3     RU     15\*10   Yes   ADC   1a   C
  14              RU       14\*14           No            ADC     1b    LL     28\*23   No    ADC   1c   C
  15              LL       57\*43           No            ADC     3     RL     18\*15   No    ADC   1b   C
  16              RU       12\*9            Yes           ADC     1b    LL     13\*11   Yes   ADC   1a   D
  17             LCW       60\*37           No            ADC     1c    RU     23\*19   No    ADC   1c   E

ADC, adenocarcinoma; GGO, ground glass opacity; LCW, left chest wall; LL, left lower lobe; LU, left upper lobe; MPR, multiple pulmonary resection; NA, not available; RL, right lower lobe; RM, right middle lobe; RU, right upper lobe; SQC, squamous cell carcinoma.

The oncological efficacy of MPR {#tca12790-sec-0011}
-------------------------------

Fifty of the 67 patients (75%) underwent synchronous MPR, with a median follow‐up duration of 43 months. The median OS and DFS were 146 and 70 months, respectively. The five‐year OS and DFS were 83.3% and 66.2%, respectively. There were no significant differences in five‐year OS and DFS between the patients who underwent MPR and the 250 propensity score‐matched patients (1:5) who underwent solitary major pulmonary resection and were matched based on age, gender, histological type, clinical tumor node metastasis stage, and neoadjuvant therapy (5‐year OS 84.5% vs. 69.0%, log rank *P* = 0.112; DFS 64.4% vs. 58.0%, log rank *P* = 0.278) (Fig [1](#tca12790-fig-0001){ref-type="fig"}).

![Survival comparison between the synchronous multiple pulmonary resection (MPR) and the matched solitary major pulmonary resection (SMPR) groups: (**a**) overall survival (OS) and (**b**) disease‐free survival (DFS). Survival comparison between the metachronous MPR and non‐surgery groups: (**c**) OS and (**d**) progression‐free survival (PFS). (![](TCA-9-1062-g004.jpg "image")) MPR, (![](TCA-9-1062-g003.jpg "image")) SMPR, and (![](TCA-9-1062-g001.jpg "image")) non‐surgery.](TCA-9-1062-g002){#tca12790-fig-0001}

Seventeen of the 67 patients (25%) underwent metachronous MPR. Their five‐year OS after the first operation was 94.1%, which was significantly better than that of the non‐surgical control group (5‐year OS 50.7%, log rank *P* = 0.005). The five‐year PFS after the second operation was 53.9%, whereas the five‐year PFS in the non‐surgical control group (*n* = 19) was only 10.5% (log rank *P* = 0.020).

The surgical safety of MPR {#tca12790-sec-0012}
--------------------------

No postoperative death occurred among the 67 patients with MPR. The most common postoperative complications were: atelectasis (4.5%), pneumonia (3.0%), prolonged air leak (3.0%), and pleural effusion (3.0%); there were no complications graded higher than IIIa. Between 2010 and 2014, 1112 solitary lung cancer patients underwent major pulmonary resections in our prospective database. The proportions of grade I--II and grade IIIa complications were 7.3% (81/1112) and 3.1% (34/1112), respectively.

Discussion {#tca12790-sec-0013}
==========

The standard surgery for lung cancer is anatomic pulmonary resection, and non‐surgical treatment is traditionally chosen for local regional recurrent or second primary lung cancer after initial pulmonary resection because of the difficulty of a second operation and poor pulmonary function capacity. With the advances in multiple specialties related to lung cancer treatment, repeated pulmonary resections for local regional recurrent or second primary lung cancer after prior surgery have become clinically commonplace in thoracic surgery. However, little is known about the long‐term survival of patients who undergo MPR. The surgical safety of MPR is another issue of great significance.

The oncological efficacy of synchronous MPR {#tca12790-sec-0014}
-------------------------------------------

The current study included a total of 50 patients who underwent synchronous MPR; their five‐year OS and DFS were 83.3% and 66.2%, respectively. The differences in five‐year OS and DFS between the synchronous MPR group and the matched control group (*n* = 250) were not statistically significant. Moreover, the survival results in this study were similar to those in relevant previous reports (Table [3](#tca12790-tbl-0003){ref-type="table"}). This indicates that except for those with confirmed poor prognostic features, such as N2/N3 stage, all synchronous multiple pulmonary lesions should be treated as multiple primary lung cancer instead of pulmonary metastasis because patients with multiple primary lung cancer can obtain favorable long‐term survival after aggressive local treatment. Additionally, the principle of resection sequence for bilateral multifocal lesions was introduced in our previous retrospective study, with a higher priority given to sublobar resections of minor lesions located in the subdominant lobes and a lower priority to lobectomies of major lesions located in the dominant lobes.[28](#tca12790-bib-0028){ref-type="ref"}

###### 

Clinicopathologic characteristics and therapeutic outcomes of cases in previous relevant literature

  Items                                                           Patients (n)   Predominant histology (%)   Extent of resection, N (%)     *P*     Postoperative mortality (%)   Five‐year survival (%)                  
  -------------------------------------------------------------- -------------- --------------------------- ---------------------------- --------- ----------------------------- ------------------------ --------- ----- ------
  Metachronous                                                                                                                                                                                                            
  Deschamps *et al*.[5](#tca12790-bib-0005){ref-type="ref"}            44                SQC (52)                      4 (9)              36 (81)              3 (7)                      0 (0)             1 (2)    4.5   33.8
  Rosengart *et al*.[6](#tca12790-bib-0006){ref-type="ref"}            78                SQC (50)                     21 (27)             32 (41)              4 (5)                      0 (0)             0 (0)    2.4    70
  Faber *et al*.[7](#tca12790-bib-0007){ref-type="ref"}               114                SQC (42)                     64 (56)             25 (22)              0 (0)                      0 (0)            23 (20)    9     33
  Antakli *et al*.[8](#tca12790-bib-0008){ref-type="ref"}              39                   NA                        20 (51)             5 (13)               0 (0)                      0 (0)            6 (23)    NA     23
  Adebonojo *et al*.[9](#tca12790-bib-0009){ref-type="ref"}            37                ADC (62)                      0 (0)               1 (3)              21(57)                      8 (22)           7 (18)    5.6    37
  Okada *et al*.[10](#tca12790-bib-0010){ref-type="ref"}               29                SQC (55)                        NA                 NA                  NA                          NA               NA       0     33
  Voltolini *et al*.[11](#tca12790-bib-0011){ref-type="ref"}           15                ADC (47)                      0 (0)              13 (87)              0 (0)                      0 (0)            2 (13)     7     43
  Asaph *et al*.[12](#tca12790-bib-0012){ref-type="ref"}               37                ADC (60)                      8 (22)             17 (46)              1 (3)                      0 (0)            10 (27)    5     28
  Rea *et al*.[13](#tca12790-bib-0013){ref-type="ref"}                 61                ADC (NA)                     26 (43)             29 (48)              0 (0)                      0 (0)            6 (10)     2     51
  Aziz *et al*.[14](#tca12790-bib-0014){ref-type="ref"}                41                SQC (39)                      2 (5)              29 (48)              0 (0)                      0 (0)            11 (27)   7.5    44
  Rice *et al*.[15](#tca12790-bib-0015){ref-type="ref"}                49                ADC (45)                     13 (27)             15 (31)              0 (0)                      0 (0)             3 (6)     0     NA
  Battafarano *et al*.[16](#tca12790-bib-0016){ref-type="ref"}         69                ADC (58)                     34 (49)             29 (42)              2 (3)                      0 (0)             4 (6)     6     33
  Riquet *et al*.[17](#tca12790-bib-0017){ref-type="ref"}             116              ADC, SQC (44)                  35 (30)             45 (39)              0 (0)                      0 (0)            36 (31)   13     32
  Haraguchi *et al*.[18](#tca12790-bib-0018){ref-type="ref"}           30                ADC (60)                     18 (60)             7 (23)               0 (0)                      0 (0)            5 (17)    10     65
  Bae *et al*.[19](#tca12790-bib-0019){ref-type="ref"}                 40                ADC (48)                      7 (18)             7 (18)               0 (0)                      0 (0)            9 (23)     5     48
  Ishigaki *et al*.[20](#tca12790-bib-0020){ref-type="ref"}            14                ADC (79)                     10 (71)             4 (29)               0 (0)                      0 (0)             0 (0)     0     NA
  Synchronous                                                                                                                                                                                                             
  Deschamps *et al*.[5](#tca12790-bib-0005){ref-type="ref"}            36                ADC (44)                      8 (22)             18 (50)              3 (8)                      0 (0)            10 (28)   5.6   15.7
  Rosengart *et al*.[6](#tca12790-bib-0006){ref-type="ref"}            33                SQC (63)                      4 (12)             11 (33)              3 (9)                      6 (18)           6 (18)     2     44
  Antakli *et al*.[8](#tca12790-bib-0008){ref-type="ref"}              26                SQC (58)                     11 (42)             5 (19)               0 (0)                      0 (0)            23 (20)   NA     12
  Adebonojo *et al*.[9](#tca12790-bib-0009){ref-type="ref"}            15              ADC, SQC (80)                   4 (27)              0 (0)              8 (53)                      1 (7)            2 (13)     0     0
  Okada *et al*.[10](#tca12790-bib-0010){ref-type="ref"}               28                ADC (54)                      2 (7)              23 (82)              0 (0)                      0 (0)             2 (7)     0     70
  Rea *et al*.[13](#tca12790-bib-0013){ref-type="ref"}                 19                ADC (NA)                      3 (16)              0 (0)              3 (16)                     11 (58)           2 (11)     5     20
  Aziz *et al*.[14](#tca12790-bib-0014){ref-type="ref"}                10                SQC (80)                      0 (0)               0 (0)              2 (20)                      1 (10)           3 (30)     0     10
  Chang *et al*.[21](#tca12790-bib-0021){ref-type="ref"}               92                ADC (87)                     10 (11)             53 (58)              8 (9)                     14 (15)            6 (7)     1     35
  Rostad *et al*.[22](#tca12790-bib-0022){ref-type="ref"}              94                ADC (54)                      4 (4)              30 (33)              8 (9)                     11 (12)           41 (44)    9     27
  Riquet *et al*.[17](#tca12790-bib-0017){ref-type="ref"}             118                ADC (58)                     19 (16)             58 (49)              0 (0)                      0 (0)            41 (35)    5     26
  Voltolini *et al*.[23](#tca12790-bib-0023){ref-type="ref"}           43                ADC (65)                      4 (9)               0 (0)              12 (28)                    16 (37)            3 (7)     7     34
  Kocaturk *et al*.[24](#tca12790-bib-0024){ref-type="ref"}            26                SQC (88)                     10 (38)             6 (23)               0 (0)                      0 (0)            10 (38)    8     50
  Yu *et al*.[25](#tca12790-bib-0025){ref-type="ref"}                  97                ADC (76)                     14 (15)             39 (40)              8 (8)                     36 (37)            0 (0)     0     70
  Yang *et al*.[26](#tca12790-bib-0026){ref-type="ref"}               101                ADC (68)                     13 (13)              0 (0)              35 (35)                    49 (49)            0 (0)     0     75
  Chen *et al*.[27](#tca12790-bib-0027){ref-type="ref"}                96                ADC (84)                     21 (22)             19 (20)             10 (10)                    46 (48)            0 (0)    NA     76

ADC, adenocarcinoma; L + L, lobectomy + lobectomy; L, lobectomy; NA, not available; P, pneumonectomy; P/L + S/W, pneumonectomy/lobectomy + segmentectomy/wedge resection; S/W, segmentectomy/wedge resection; SQC, squamous cell carcinoma.

The oncological efficacy of metachronous MPR {#tca12790-sec-0015}
--------------------------------------------

The five ‐year OS of the 17 patients who underwent metachronous MPR was 94.1%, and the five‐year PFS after the second operation was 53.9%, both of which were significantly better survival outcomes than those of the non‐surgical control group and the outcomes presented in previous reports (Table [3](#tca12790-tbl-0003){ref-type="table"}).

In our previous study, we retrospectively reviewed the data of 416 consecutive stage I non‐small cell lung cancer patients in our prospective database who underwent major pulmonary resections between 2000 and 2013 by a single surgeon team.[29](#tca12790-bib-0029){ref-type="ref"} A total of 76 cases (18.3%) had local regional recurrence or remote metastasis during the follow‐up period, and the most frequent site of recurrence was the lung (21 cases, 5%). The accumulated two and five‐year pulmonary recurrence rates were 2.3% (95% confidence interval 0.7--3.9%) and 4.8% (95% confidence interval 2.6--7.0%), respectively. These results indicate that postoperative follow‐up for lung cancer patients is necessary in order to detect local regional recurrence, remote metastasis, and second primary lung cancer as early as possible. As long as the pulmonary function reserve is adequate without high‐risk comorbidities, an aggressive surgical treatment could also provide more favorable long‐term survival.

Postoperative safety of MPR {#tca12790-sec-0016}
---------------------------

In the current study, we carefully reviewed the data of 67 patients with MPR and found there was neither postoperative mortality within 30 days nor severe postoperative complications greater than grade IIIa among both synchronous and metachronous MPR cases. The overall postoperative complication rate of the whole group was 9.3%, which was similar to the rate in patients that underwent solitary major pulmonary resections (10.3%).[30](#tca12790-bib-0030){ref-type="ref"} This result was also similar to those of previous reports (Table [3](#tca12790-tbl-0003){ref-type="table"}), indicating that the surgical safety of MPR is comparable to that of solitary major pulmonary resections.

In summary, to circumvent the issue of the difficulty of differential diagnosis between metastatic or second primary lung cancers, as long as rigorous selection criteria based on tumor biology and surgical principles are followed, MPR is potentially safe and effective. Of course, the current study has some limitations. First, although the clinical data were derived from our prospective lung cancer database, selection bias is innate to the retrospective nature of the study. Second, the limited number of non‐surgery cases made propensity score matching infeasible, which could have resulted in inappropriate results and conclusions. Third, the small sample size undermines the reliability of the study results.

Nevertheless, these promising results justify planning a multicenter trial involving a larger cohort of patients. This study provides pilot data to enable more accurate power calculations to determine the required sample size for the desired outcome measures.
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